JAK inhibitors:
Baricitinib is a well-known anti-inflammatory drug and a potent
inhibitor of AAK1 involved in endocytosis. The adverse outcome which is
reported significantly is upper respiratory tract infection.[9]Although the therapeutic doses reduce
inflammation, the infectivity of the virus is not reduced. Therefore,
combination therapy can be proved beneficial due to less drug
interaction. Combination therapy trials have been initiated. One
open-label non-randomized trial uses this therapy to treat moderate and
severe patients of COVID-19. Moreover, other trials treat patients with
SARS CoV-2 pneumonia with this combination therapy41.